000309656 001__ 309656
000309656 005__ 20260205152941.0
000309656 0247_ $$2doi$$a10.1007/s00277-026-06776-w
000309656 0247_ $$2pmid$$apmid:41636849
000309656 0247_ $$2ISSN$$a0939-5555
000309656 0247_ $$2ISSN$$a0006-5242
000309656 0247_ $$2ISSN$$a1432-0584
000309656 037__ $$aDKFZ-2026-00288
000309656 041__ $$aEnglish
000309656 082__ $$a610
000309656 1001_ $$aGeorgi, Julia-Annabell$$b0
000309656 245__ $$aRelapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical cases.
000309656 260__ $$aNew York$$bSpringer$$c2026
000309656 3367_ $$2DRIVER$$aarticle
000309656 3367_ $$2DataCite$$aOutput Types/Journal article
000309656 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770301773_2392441
000309656 3367_ $$2BibTeX$$aARTICLE
000309656 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309656 3367_ $$00$$2EndNote$$aJournal Article
000309656 500__ $$a#NCTZFB9#
000309656 520__ $$aThe clinical success of FLT3 inhibitors has led to their steadily increasing use in the treatment of acute myeloid leukemia (AML), both in the relapsed/refractory setting and as post-transplant maintenance. Despite their expanding application, there is currently no guidance on the optimal duration of therapy or the feasibility of discontinuation. In the maintenance context, current practice is largely based on trial protocols with predefined treatment periods, yet relapses after cessation have been documented. Similarly, in the relapsed/refractory setting, the management of long-term responders to FLT3-directed monotherapy lacks evidence-based guidance.We report two cases of FLT3-ITD AML patients with relapse after discontinuation of prolonged FLT3 inhibitor therapy, despite sustained remission prior to withdrawal. As such scenarios remain insufficiently characterized in the literature, these case vignettes are presented to highlight the unresolved challenge of defining the appropriate duration of FLT3 inhibitor therapy and to underscore the need for systematic evaluation to establish evidence-based strategies for safe discontinuation or extended administration.
000309656 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309656 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309656 650_7 $$2Other$$aFLT3 inhibitor
000309656 650_7 $$2Other$$aFLT3-ITD AML
000309656 650_7 $$2Other$$aGilteritinib
000309656 650_7 $$2Other$$aMeasurable residual disease (MRD)
000309656 650_7 $$2Other$$aPost-transplant maintenance
000309656 650_7 $$2Other$$aRelapse
000309656 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$afms-Like Tyrosine Kinase 3
000309656 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aFLT3 protein, human
000309656 650_7 $$2NLM Chemicals$$aProtein Kinase Inhibitors
000309656 650_2 $$2MeSH$$aHumans
000309656 650_2 $$2MeSH$$afms-Like Tyrosine Kinase 3: antagonists & inhibitors
000309656 650_2 $$2MeSH$$afms-Like Tyrosine Kinase 3: genetics
000309656 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: drug therapy
000309656 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: genetics
000309656 650_2 $$2MeSH$$aMale
000309656 650_2 $$2MeSH$$aMiddle Aged
000309656 650_2 $$2MeSH$$aProtein Kinase Inhibitors: administration & dosage
000309656 650_2 $$2MeSH$$aProtein Kinase Inhibitors: therapeutic use
000309656 650_2 $$2MeSH$$aRecurrence
000309656 650_2 $$2MeSH$$aFemale
000309656 650_2 $$2MeSH$$aAdult
000309656 7001_ $$aRöllig, Christoph$$b1
000309656 7001_ $$aSchetelig, Johannes$$b2
000309656 7001_ $$aThiede, Christian$$b3
000309656 7001_ $$aBrückmann, Sascha$$b4
000309656 7001_ $$0P:(DE-He78)2a9091646ed378ef030a77fd32aedf79$$aBornhäuser, Martin$$b5
000309656 7001_ $$aMiddeke, Jan Moritz$$b6
000309656 773__ $$0PERI:(DE-600)1458429-3$$a10.1007/s00277-026-06776-w$$gVol. 105, no. 3, p. 82$$n3$$p82$$tAnnals of hematology$$v105$$x0939-5555$$y2026
000309656 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2a9091646ed378ef030a77fd32aedf79$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000309656 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309656 9141_ $$y2026
000309656 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-27$$wger
000309656 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-27$$wger
000309656 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN HEMATOL : 2022$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000309656 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-27
000309656 9201_ $$0I:(DE-He78)DD04-20160331$$kDD04$$lKoordinierungsstelle NCT Dresden$$x0
000309656 980__ $$ajournal
000309656 980__ $$aVDB
000309656 980__ $$aI:(DE-He78)DD04-20160331
000309656 980__ $$aUNRESTRICTED